Intelligent Bio Solutions Announces Completion of Interference Study

What Happened

• On August 3, 2026, Intelligent Bio Solutions, Inc. (NASDAQ: INBS) announced via press release that it completed its Interference Study for the Intelligent Fingerprinting Drug Screening System. The company furnished the press release as Exhibit 99.1 to its Form 8‑K under Item 7.01 (Regulation FD Disclosure). The filing notes the disclosure is qualified by the full text of the press release.

Key Details

• Company: Intelligent Bio Solutions, Inc. (INBS).
• Event: Completion of the Interference Study for the Intelligent Fingerprinting Drug Screening System.
• Filing: Current Report on Form 8‑K dated August 3, 2026; press release attached as Exhibit 99.1.
• Item reported: 7.01 (Regulation FD Disclosure).

Why It Matters

• This announcement documents a technical milestone for INBS’s drug screening product — completion of an interference study is a step toward validating test performance and supporting regulatory or commercial efforts.
• For investors, the filing signals progress on product development and can be used to track upcoming regulatory submissions, commercialization updates, or further technical results disclosed by the company.